Post-INFECT: Investigating Neuroinflammation and its effects in post-COVID syndrome

Prior treatment

• The subject is actively using anti-inflammatory drugs

Other illness

• The subject has an already known psychiatric, somatic or neurodegenerative condition that can explain his/her complaints

Other

• The subject is unable to lay still for scanning due to claustrophobia, severe back pain or trypanophobia (fear of needles)
• The subject is of female sex with childbearing potential and not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception. Females of childbearing potential must orally and in writing confirm not to be pregnant or breastfeeding at the time of screening and at the day of the PET scan

• The subject was diagnosed with mild symptomatic COVID-19, confirmed by a positive PCR for SARS- CoV-2, positive SARS-CoV-2 serology or CO-RADS (COVID-19 Reporting and Data System) 4 or 5 on CT-scan, or antigen quicktest, or had typical symptoms and was part of a household in which another person was tested positive by PCR 2 weeks before or after the first day of illness
• The subject is at least one year after being diagnosed with COVID-19
• Subjects with persistent post-COVID complaints experience severe levels of fatigue (≥ 35) on the fatigue subscale of the Checklist Individual Strength [CIS-fatigue]) and/or difficulty concentrating (≥18) on the concentration subscale of the Checklist Individual Strength [CIS-concentration]. Control subjects without persistent complaints experiences no fatigue (<35) on the CIS-fatigue and no difficulty concentrating (<18) on the CIS-concentration
• The subject is in the range 30-65 years of age
• The subject has sufficient command of the Dutch language